Cancer treatment developer Rakuten Medical has received $100m in series C1 capital from affiliate Rakuten, which now holds a 22.6% stake.
E-commerce firm Rakuten has provided $100m in series C1 financing for Rakuten Medical, the US-based cancer-focused biotechnology developer formerly known as Aspyrian Therapeutics.
Rakuten now owns 22.6% of the company, which will become an equity-method affiliate in Q3 2019. The series C1 round follows a $284m series C round closed in December 2018 that featured a $134m extension from Rakuten and financial services firm SBI Group.
The series C round’s $150m first tranche was led by Hiroshi Mikitani,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
